DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
SGI-1776 is an investigational drug.
There have been 27 clinical trials for SGI-1776. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2017.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, and Leukemia, Myeloid. The leading clinical trial sponsors are Astex Pharmaceuticals, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.
There are thirty-eight US patents protecting this investigational drug and two hundred and seventy-two international patents.
Recent Clinical Trials for SGI-1776
|Testing the Combination of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma||National Cancer Institute (NCI)||Phase 2|
|Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer||Astex Pharmaceuticals||Phase 1/Phase 2|
|Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer||Bristol-Myers Squibb||Phase 1/Phase 2|
Top disease conditions for SGI-1776
Top clinical trial sponsors for SGI-1776
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|SGI-1776||Get Started Free||Bicyclic fused pyrimidine compounds as TAM inhibitors||Incyte Corporation (Wilmington, DE)||Get Started Free|
|SGI-1776||Get Started Free||Pyrrolopyrimidine derivatives as TAM inhibitors||Incyte Corporation (Wilmington, DE)||Get Started Free|
|SGI-1776||Get Started Free||Compositions and methods for treating cancer with JAK2 activity||DUKE UNIVERSITY (Durham, NC)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|SGI-1776||World Intellectual Property Organization (WIPO)||WO2017027717||2035-08-12||Get Started Free|
|SGI-1776||World Intellectual Property Organization (WIPO)||WO2017035366||2035-08-26||Get Started Free|
|SGI-1776||World Intellectual Property Organization (WIPO)||WO2015051252||2033-10-03||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|